483 related articles for article (PubMed ID: 25200104)
41. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat.
Roda A; Pellicciari R; Gioiello A; Neri F; Camborata C; Passeri D; De Franco F; Spinozzi S; Colliva C; Adorini L; Montagnani M; Aldini R
J Pharmacol Exp Ther; 2014 Jul; 350(1):56-68. PubMed ID: 24784847
[TBL] [Abstract][Full Text] [Related]
42. Marine sponge steroids as nuclear receptor ligands.
Fiorucci S; Distrutti E; Bifulco G; D'Auria MV; Zampella A
Trends Pharmacol Sci; 2012 Nov; 33(11):591-601. PubMed ID: 23000093
[TBL] [Abstract][Full Text] [Related]
43. FXR signaling in the enterohepatic system.
Matsubara T; Li F; Gonzalez FJ
Mol Cell Endocrinol; 2013 Apr; 368(1-2):17-29. PubMed ID: 22609541
[TBL] [Abstract][Full Text] [Related]
44. Cholestasis-induced bile acid elevates estrogen level via farnesoid X receptor-mediated suppression of the estrogen sulfotransferase SULT1E1.
Liu X; Xue R; Yang C; Gu J; Chen S; Zhang S
J Biol Chem; 2018 Aug; 293(33):12759-12769. PubMed ID: 29929982
[TBL] [Abstract][Full Text] [Related]
45. Hepatoprotection of auraptene from the peels of citrus fruits against 17α-ethinylestradiol-induced cholestasis in mice by activating farnesoid X receptor.
Wang J; Fu T; Dong R; Wang C; Liu K; Sun H; Huo X; Ma X; Yang X; Meng Q
Food Funct; 2019 Jul; 10(7):3839-3850. PubMed ID: 31210195
[TBL] [Abstract][Full Text] [Related]
46. Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis.
Hao H; Cao L; Jiang C; Che Y; Zhang S; Takahashi S; Wang G; Gonzalez FJ
Cell Metab; 2017 Apr; 25(4):856-867.e5. PubMed ID: 28380377
[TBL] [Abstract][Full Text] [Related]
47. Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders.
Molinaro A; Marschall HU
Biochem Soc Trans; 2022 Feb; 50(1):361-373. PubMed ID: 35191955
[TBL] [Abstract][Full Text] [Related]
48. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
49. Targeting FXR in Cholestasis.
Keitel V; Dröge C; Häussinger D
Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
[TBL] [Abstract][Full Text] [Related]
50. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents.
Boyer JL; Trauner M; Mennone A; Soroka CJ; Cai SY; Moustafa T; Zollner G; Lee JY; Ballatori N
Am J Physiol Gastrointest Liver Physiol; 2006 Jun; 290(6):G1124-30. PubMed ID: 16423920
[TBL] [Abstract][Full Text] [Related]
51. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations.
Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883
[TBL] [Abstract][Full Text] [Related]
52. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
[TBL] [Abstract][Full Text] [Related]
53. Progress and challenges of selective Farnesoid X Receptor modulation.
Massafra V; Pellicciari R; Gioiello A; van Mil SWC
Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033
[TBL] [Abstract][Full Text] [Related]
54. Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids.
Erichsen TJ; Aehlen A; Ehmer U; Kalthoff S; Manns MP; Strassburg CP
J Hepatol; 2010 Apr; 52(4):570-8. PubMed ID: 20189675
[TBL] [Abstract][Full Text] [Related]
55. [FXR modulators and cholestatic diseases.].
Alvaro D; Bragazzi MC; Venere R; Ridola L
Recenti Prog Med; 2021 Feb; 112(2):124-127. PubMed ID: 33624625
[TBL] [Abstract][Full Text] [Related]
56. Nuclear receptors as therapeutic targets in cholestatic liver diseases.
Zollner G; Trauner M
Br J Pharmacol; 2009 Jan; 156(1):7-27. PubMed ID: 19133988
[TBL] [Abstract][Full Text] [Related]
57. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy.
Van Mil SW; Milona A; Dixon PH; Mullenbach R; Geenes VL; Chambers J; Shevchuk V; Moore GE; Lammert F; Glantz AG; Mattsson LA; Whittaker J; Parker MG; White R; Williamson C
Gastroenterology; 2007 Aug; 133(2):507-16. PubMed ID: 17681172
[TBL] [Abstract][Full Text] [Related]
58. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
Fiorucci S; Di Giorgio C; Distrutti E
Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
[TBL] [Abstract][Full Text] [Related]
59. β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.
Thompson MD; Moghe A; Cornuet P; Marino R; Tian J; Wang P; Ma X; Abrams M; Locker J; Monga SP; Nejak-Bowen K
Hepatology; 2018 Mar; 67(3):955-971. PubMed ID: 28714273
[TBL] [Abstract][Full Text] [Related]
60. FXR: a promising target for the metabolic syndrome?
Cariou B; Staels B
Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
